Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
June 19 2020 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercialising
oral immunotherapeutics for the prevention and treatment of gut
mediated pathogens, today is pleased to provide shareholders with
an update on the progress made to date on the company’s research
collaboration with the Naval Medical Research Center (NMRC)
previously announced in October 2019.
Immuron has now executed a research agreement
with Australia’s national science agency, CSIRO. to produce the new
therapeutic against Campylobacter and Entero-Toxigenic Escherichia
coli (ETEC) for clinical evaluation by the US Department of
Defense. Under the terms of the research agreement CSIRO has been
engaged to produce a hyper-immune bovine colostrum product using
vaccines developed by the NMRC. The work will be conducted at the
Department of Agriculture and Water Resources Biosecurity Approved
Arrangement facilities located in Armidale NSW.
“This is the second R&D program CSIRO has
been engaged to undertaken recently with Immuron,” said CSIRO’s Dr
Peter Hunt, principal research scientist.
“We are pleased to once again offer the
services, expertise and facilities of CSIRO to produce this new
therapeutic product for clinical assessment by the Naval Medical
Research Center (NMRC). Approval was obtained from Biosecurity
Australia early this year to import the NMRC vaccines and they have
been in storage since the COVID-19 pandemic hit the world. I am
pleased to report the vaccination campaign has been finally
initiated and the finished product should be available by the end
of this year.”
Immuron is also pleased to inform shareholders
that the NMRC submitted the Pre-IND information package as planned
on the 10th of June 2020 and expects to receive written comments on
the non-clinical information from the U.S. Food and Drug
Administration (FDA) within 30-days regarding its planned
investigational new drug application to treat moderate to severe
campylobacteriosis and ETEC infections. The company has also
recently fully executed the Research Subaward Agreement with The
Henry M. Jackson Foundation for Advancement of Military Medicine
Inc. the Pass-Through Entity managing the Federal Award.
Immuron CEO, Dr Jerry Kanellos commented.
“We are grateful that the CSIRO is such a strong
supporter of the Australian Biotechnology Industry. The current
program is now back on track and we will have the hyper-immune
bovine colostrum harvested in September 2020. The drug substance
and drug product will be manufactured by the end of this year and
will be available for the clinical development program to prevent
acute infectious diarrhea which the NMRC plans to initiate early
next year.”
COMPANY
CONTACT: Dr Jerry Kanellos,
Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024